- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03647124
A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma
A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, 73013
- Recruiting
- Local Institution - 105
-
Graz, Austria, 8036
- Not yet recruiting
- LKH Graz Medizinische Universitätsklinik
-
Leoben, Austria, 8700
- Not yet recruiting
- LKH Hochsteiermark, Standort Leoben
-
Leoben, Austria, 8700
- Recruiting
- Local Institution - 104
-
Salzburg, Austria, 5020
- Recruiting
- Local Institution - 102
-
Salzburger, Austria, 5020
- Recruiting
- Salzburger Landeskliniken - Universitaetsklinikum Salzburg
-
Wien, Austria, 1090
- Recruiting
- AKH Wien, Universitaetsklinik fuer Innere Medizin III
-
Wien, Austria, 1090
- Recruiting
- Local Institution - 101
-
Wiener Neustadt, Austria, 2700
- Recruiting
- Landesklinikum Wiener Neustadt
-
Wiener Neustadt, Austria, 2700
- Recruiting
- Local Institution - 103
-
-
-
-
-
Brest, France, 29200
- Withdrawn
- CHRU de Brest - Hôpital Morvan
-
Caen Cedex 9, France, 14033
- Withdrawn
- CHU de Caen, institut d'hematologie de basse Nomandie
-
Le Chesnay, France, 78157
- Not yet recruiting
- Centre Hospitalier de Versailles André Mignot
-
Le Chesnay Cedex, France, 78157
- Recruiting
- Local Institution - 303
-
Le Mans, France, 72015
- Withdrawn
- Clinique Victor Hugo
-
Nantes, France, 4402
- Recruiting
- Institution: Hopital Prive du Confluent
-
Nantes, France, 4402
- Recruiting
- Local Institution - 308
-
Paris, France, 75013
- Not yet recruiting
- Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Universitaire Pitie Salpetriere (Hopital Pitie-Salpetriere)
-
Saint Quentin Picardie, France, 2321
- Recruiting
- Centre Hospitalier de Saint-Quentin
-
Toulouse CEDEX 9, France, 31059
- Recruiting
- Local Institution - 305
-
Toulouse Cedex 9, France, 31000
- Not yet recruiting
- Institut Universitaire du Cancer Toulouse - Oncopole
-
-
-
-
-
Amberg, Germany, 92224
- Withdrawn
- Gesundheitszentrum St. Marien GmbH
-
Aschaffenburg, Germany, 63739
- Withdrawn
- Studienzentrum Aschaffenburg
-
Frankfurt/ Oder Brandenburg, Germany, 15236
- Recruiting
- Berufsausuebungsgemeinschaft Kiehl/Stein
-
Garmisch-Partenkirchen Bavaria, Germany, 82467
- Withdrawn
- Klinikum Garmisch-Partenkirchen Gmbh - Zentrum Fuer Innere Medizin
-
Leipzig, Germany, 04289
- Recruiting
- Praxis fuer Haematolgie, Onkologie und Palliativmedizin
-
Wuerzburg, Germany, 97080
- Recruiting
- Universitaetsklinikum Wuerzburg
-
Wuerzburg, Germany, 97080
- Completed
- Local Institution - 256
-
-
-
-
-
Alexandrouppoli, Greece, 68100
- Not yet recruiting
- General University Hospital of Alexandroupolis
-
Athens, Greece, 11522
- Not yet recruiting
- General Anti-Cancer Hospital "Agios Savvas"
-
Athens, Greece, 11525
- Recruiting
- Local Institution - 501
-
Athens, Greece, 11525
- Recruiting
- Private hospital "Iatriko Psychikou", Athens
-
Athens, Greece, 11527
- Recruiting
- General University Hospital of Athens "LAIKO", Athens
-
Athens, Greece, GR 115-27
- Recruiting
- Local Institution - 502
-
Athens Goudi, Greece, 11527
- Recruiting
- Local Institution - 506
-
Chaidari, Greece, 12462
- Not yet recruiting
- General University Hospital "Attikon"
-
Piraeous, Greece, 18537
- Recruiting
- Metaxa Cancer Hospital, Athens
-
Rio, Patras, Greece, 265 04
- Recruiting
- Local Institution - 511
-
Thessaloniki, Greece, 54007
- Not yet recruiting
- Theageneio General Hospital, Thessaloniki
-
-
Achaïa
-
Patras, Achaïa, Greece, 26500
- Withdrawn
- Local Institution - 0617
-
-
-
-
-
Busto Arsizio, Italy, 21052
- Recruiting
- Local Institution - 601
-
Busto Arsizio, Italy, 21052
- Recruiting
- Ospedale di Busto Arsizio - ASST Valle Olona
-
Genova, Italy, 16132
- Recruiting
- Local Institution - 607
-
Genova, Italy, 16132
- Recruiting
- Ospedale Policlinico San Martino - IRCCS
-
Milano, Italy, 20141
- Recruiting
- Istituto Europeo di Oncologia
-
Milano, Italy, 20089
- Recruiting
- Istituto Clinico Humanitas IRCCS
-
Milano, Italy, 20122
- Recruiting
- Fondazione IRCCS Ca' Cranda, Ospedale Maggiore Policinico
-
Milano, Italy, 20122
- Recruiting
- Local Institution - 614
-
Milano, Italy, 20162
- Recruiting
- Azienda Ospedaliera Niguarda Ca' Granda
-
Milano, Italy, 20162
- Recruiting
- Local Institution - 603
-
Padova, Italy, 35043
- Not yet recruiting
- Local Institution - 617
-
Contact:
- Site 617
-
Padova, Italy, 35128
- Recruiting
- Azienda Ospedaliera di Padova - U.O.C. di Gastroenterologia
-
Padova, Italy, 35128
- Recruiting
- Local Institution - 613
-
Parma, Italy, 43126
- Not yet recruiting
- Azienda Ospedaliero - Universiaria di Parma
-
Pavia, Italy, 27100
- Recruiting
- Amyloidosis Research & Treatment Center, Fondazione Irccs Policlinico San Matteo
-
Pavia, Italy, 27100
- Recruiting
- Local Institution - 609
-
Pisa, Italy, 56126
- Recruiting
- Azienda Ospedaliero Universitaria Pisana
-
Pisa, Italy, 56100
- Recruiting
- Local Institution - 610
-
Reggio Emilia, Italy, 42122
- Recruiting
- Arcispedale Santa Maria Nuova - AUSL Reggio Emilia
-
Reggio Emilia, Italy, 42122
- Recruiting
- Local Institution - 602
-
Rimini, Italy, 47923
- Recruiting
- Infermi Hospital
-
Rimini, Italy, 47923
- Recruiting
- Local Institution - 605
-
Roma, Italy, 161
- Recruiting
- Policlinico Umberto I , Universita La Sapienza
-
Rome, Italy, 00161
- Recruiting
- Local Institution - 611
-
Siena, Italy, 53100
- Recruiting
- Universita di Siena -Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte
-
Siena, Italy, 53100
- Recruiting
- Local Institution - 608
-
Torino, Italy, 10126
- Recruiting
- Azienda Ospedaliera Città della Salute e della Scienza di Torino
-
Torino, Italy, 10126
- Recruiting
- Local Institution - 616
-
Torino, Italy, 10126
- Recruiting
- Presidio Ospedaliero Molinette - A.O.U. Citta della Salute e della Scieza
-
Venezia, Italy, 30174
- Recruiting
- Ospedale Dell'Angelo Di Mestre
-
Venezia - Mestre, Italy, 30174
- Recruiting
- Local Institution - 606
-
-
-
-
-
Den Haag, Netherlands, 2545 AA
- Recruiting
- HagaZiekenhuis van Den Haag - Juliana Kinderziekenhuis (JKZ) - Leyweg
-
Den Haag, Netherlands, 2545 CH
- Recruiting
- Local Institution - 401
-
-
-
-
-
Alava, Spain, 01009
- Recruiting
- Local Institution - 204
-
Alava País Vasco, Spain, 1009
- Recruiting
- Hospital Universitario de Alava
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28041
- Recruiting
- Local Institution - 207
-
Malaga, Spain, 29010
- Recruiting
- Local Institution - 201
-
Malaga, Spain, 29730
- Recruiting
- Hospital Regional Universitario Carlos Haya
-
Ourense, Spain, 32005
- Recruiting
- Hospital de Orense
-
Ourense, Spain, 32005
- Recruiting
- Local Institution - 206
-
Pamplona Navarra, Spain, 31008
- Withdrawn
- Complejo Hospitalario de Navarra
-
Salamanca, Spain, 37003
- Recruiting
- Local Institution - 202
-
Salamanca, Spain, 37007
- Recruiting
- Hospital Clínico Universiatrio de Salamanca
-
Santa Cruz De Tenerife, Spain, 38010
- Not yet recruiting
- Local Institution - 209
-
Contact:
- Site 209
-
Sevilla, Spain, 41014
- Recruiting
- Local Institution - 205
-
Sevilla, Spain, 41014
- Recruiting
- Nuestra Senora de Valme
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Received at least one dose of lenalidomide commencing after 08 July 2016 for the treatment of relapsed refractory mantle cell lymphoma.
Informed consent of the patient or an authorized third person or authority, if required by law, given prior to data collection.
Patient must be ≥18 years of age at the time of signing the informed consent form.
Exclusion Criteria:
1) Patients will be excluded if they were participating in an interventional clinical trial during the treatment period under observation in this Post Authorization Safety Study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lenalidomide treated Relapsed or refractory mantle cell lymphoma (R/R-MCL) participants in Europe
|
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To quantify and characterize the event of TFR by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting.
Time Frame: Approximately 8.5 years
|
To quantify and characterize the event of TFR by tumor burden (assessed based on the last CT scan performed within a maximum of 2 months prior to initiation of administration of lenalidomide) in R/R MCL patients treated with lenalidomide in a real-world setting.
|
Approximately 8.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To quantify and characterize the proportion of early deaths by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting
Time Frame: Approximately 8.5 years
|
To quantify and characterize the proportion of early deaths (defined as deaths within 20 weeks of initial administration of lenalidomide) by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting.
|
Approximately 8.5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Mantle-Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- CC-5013-MCL-005
- U1111-1213-1816 (REGISTRY: WHO)
- EUPAS23366 (REGISTRY: EU PAS Register)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Mantle-Cell
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCActive, not recruitingStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell LymphomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Ann Arbor Stage I Mantle Cell Lymphoma | Ann Arbor Stage II Mantle Cell Lymphoma | Ann Arbor Stage III Mantle Cell Lymphoma | Ann Arbor Stage IV Mantle Cell LymphomaUnited States
-
Burzynski Research InstituteWithdrawnRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell LymphomaUnited States
-
BeiGeneRecruitingMantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
-
BeiGeneCompletedRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaChina
-
Fondazione Italiana Linfomi - ETSRecruitingRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaItaly
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell LymphomaUnited States
Clinical Trials on Lenalidomide
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Groupe Francophone des MyelodysplasiesUnknownMyelodysplastic SyndromesFrance